tldrdailynews.com logo
Tag

Parp Inhibitors

All articles tagged with #parp inhibitors

Aging signs can mask ovarian cancer: Minnesota survivor’s warning
health25 days ago

Aging signs can mask ovarian cancer: Minnesota survivor’s warning

A Minnesota woman, Becky Drexler, learned the hard way that vague symptoms like urinary changes, bloating and hip pain can signal ovarian cancer rather than aging, after her best friend died from the disease; she was diagnosed at stage 3B in 2018, underwent surgery, six rounds of chemotherapy, and radiation, then took the PARP inhibitor Lynparza with years of no evidence of disease before a 2026 recurrence around her small intestine requiring further treatment; doctors note there’s no reliable routine screening for ovarian cancer at average risk, underscoring the need for self-advocacy and specialized gynecologic-oncology care to improve early detection and outcomes.

via Fox News|
#early-detection#health#ovarian-cancer
Pfizer widens PARP advantage in prostate cancer with Talzenna-Xtandi combo
health4 months ago

Pfizer widens PARP advantage in prostate cancer with Talzenna-Xtandi combo

Pfizer reports phase 3 Talapro-3 showing adding Talzenna to Xtandi cuts radiographic progression-free survival risk by 52% in HRR-gene–mutated metastatic castration-sensitive prostate cancer, with benefits across BRCA and non-BRCA subgroups. At three years, PFS favored the combo (77% vs 56%), and interim overall survival trended 23% higher. Safety was mainly anemia; 51% grade 3+ in the combo vs 3% in control. The results contrast with J&J’s Akeega, whose benefit was driven largely by BRCA2 mutations, suggesting a broader potential patient population after genetic testing.

via Fierce Pharma|
#health#hrr-genes#parp-inhibitors
BRCA2 Germline Variants and RB1 Loss Drive CDK4/6 Resistance in Breast Cancer
health7 months ago

BRCA2 Germline Variants and RB1 Loss Drive CDK4/6 Resistance in Breast Cancer

A large clinicogenomic analysis of 5,881 breast cancer patients shows germline BRCA2 mutations predispose tumors to acquire RB1 loss under CDK4/6 inhibitor pressure, aided by baseline RB1 hemizygosity and ongoing homologous recombination deficiency. This RB1 loss drives resistance to frontline CDK4/6 inhibitors, while PARP inhibitors outperform CDK4/6 inhibitors across models and data. The study proposes prioritizing PARP inhibition for gBRCA2 carriers to intercept RB1‑loss trajectories and delay resistance, and provides a predictive framework using pre-treatment germline/somatic context and mutational signatures to forecast resistance trajectories.

via Nature|
#brca2#cdk46-inhibitors#health
Gene-tailored drug combo halves Graham's tumour in cancer breakthrough with wider potential
health8 months ago

Gene-tailored drug combo halves Graham's tumour in cancer breakthrough with wider potential

Graham Caveney, diagnosed with stage-four oesophageal cancer and given about a year to live, saw his tumour shrink by half and his condition stabilise after joining an early-stage Petra trial at The Christie hospital. The trial combines a PARP inhibitor (AZD5305) with trastuzumab deruxtecan (Enhertu), and its approach fingerprints tumours by genetic mutations rather than cancer type, with early signs that the same drug combo is helping breast cancer as well. While Graham faced a rare breathing complication that led to withdrawal after a year, doctors are optimistic that this personalised, gene-focused treatment could become standard care and benefit many cancer patients across tumour types.

via Daily Mail|
#azd5305#cancer#health